New clinical research entity formed in a three-company merger
New Zealand’s P3 Research and Australia’s AusTrials and Holdsworth House have announced a merger to form Momentum Clinical Research, an extensive clinical research entity with sites that have been operating for more than 20 years.
The new multi-site entity can facilitate a variety of therapeutic clinical trials, from healthy volunteer studies including vaccinations to studies of general medical conditions, chronic pain and specialised areas, such as obesity, dermatology and HIV.
Momentum Clinical Research CEO Joshua Stent said the entity works as a one-stop solution for research organisations and biotech companies looking to host clinical trials in Australia and New Zealand.
“Our centralised approach to feasibility and accelerated start-up process not only enhances capacity at our sites but also enables our research teams to prioritise what matters most. This empowers them to focus on the quality delivery of clinical trials, while simultaneously ensuring improved access for those seeking to participate in trials,” Stent said.
“The merging of P3 Research, AusTrials and Holdsworth House to form Momentum Clinical Research will enable us to create an even bigger impact in the world of clinical research and we are looking forward to seeing these brands collaborate and share their proven track records of success across the board,” Stent said.
“As one organisation, we can offer a streamlined and efficient process for our partners, providing confidence to deliver high-quality studies efficiently, achieved through the centralisation of our feasibility and study start-up teams, and our deep expertise in rapidly recruiting participants.
“The collaboration of the three brands will allow trial sponsors and clinical research organisations the opportunity to host clinical trials across multiple sites in both Australia and New Zealand, with access to a comprehensive database of over 50,000 potential participants,” Stent said.
P3 Research Managing Director Dr Richard Stubbs said Momentum Clinical Research’s facilities are equipped to host a diverse range of studies throughout their different phases, with further plans for expansion to meet the demand of both local and international trials.
“Our study coordinators are fully trained with a current GCP certification and are proficient in all the leading electronic case report form and randomisation platforms. Additionally, some coordinators have completed further certifications with the International Air Transport Association on the shipment of dangerous goods,” Stubbs said.
Too much UPF could speed up biological ageing
UPFs include foods such as chips, carbonated drinks, instant noodles, ice cream, chocolate,...
Top international gong for SA-based NDIS provider
South Australian NDIS provider Utopia Care has won its second major award — being...
Depressive disorders: 70% of Australians not getting adequate treatment
Minimally adequate treatment is defined as at least one month of medication in addition to four...
